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Abstract Cytosolic and mitochondrial human branched
chain aminotransferase (hBCATc and hBCATm, respec-
tively) play an integral role in brain glutamate metabolism.
Regional increased levels of hBCATc in the CA1 and CA4
region of Alzheimer’s disease (AD) brain together with
increased levels of hBCATm in frontal and temporal cortex
of AD brains, suggest a role for these proteins in glutamate
excitotoxicity. Glutamate toxicity is a key pathogenic
feature of several neurological disorders including epilepsy
associated dementia, AD, vascular dementia (VaD) and
dementia with Lewy bodies (DLB). To further understand
if these increases are specific to AD, the expression profiles
of hBCATc and hBCATm were examined in other forms of
dementia including DLB and VaD. Similar to AD, levels of
hBCATm were significantly increased in the frontal and
temporal cortex of VaD cases and in frontal cortex of DLB
cases compared to controls, however there were no
observed differences in hBCATc between groups in these
areas. Moreover, multiple forms of hBCATm were
observed that were particular to the disease state relative to
matched controls. Real-time PCR revealed similar
expression of hBCATm mRNA in frontal and temporal
cortex for all cohort comparisons, whereas hBCATc
mRNA expression was significantly increased in VaD
cases compared to controls. Collectively our results suggest
that hBCATm protein expression is significantly increased
in the brains of DLB and VaD cases, similar to those
reported in AD brain. These findings indicate a more global
response to altered glutamate metabolism and suggest
common metabolic responses that might reflect shared
neurodegenerative mechanisms across several forms of
dementia.
Keywords Branched chain aminotransferase 
hBCATm  hBCATc  Glutamate  Alzheimer’s disease 
Vascular dementia  Dementia with Lewy body
Introduction
Alzheimer’s disease (AD) represents 64 % of all dementia
cases, followed by dementia with Lewy bodies (DLB) and
vascular dementia (VaD) [1]. In addition to specific neu-
ropathology observed post-mortem (such as deposition of
amyloid plaques and neurofibrillary tangles), several neu-
rotransmitter profiles are compromised in AD brain, such
as the cholinergic system and glutamate [2, 3]. Glutamate
is the major excitatory neurotransmitter in the central
nervous system (CNS) [4], plays a key role in dendrite/
synapse formation and plasticity [5], and is important for
learning and memory [6]. Levels of glutamate must be
tightly regulated since excitotoxicity causes cellular cal-
cium overload, resulting in neuronal cell death, a patho-
genic feature associated with AD [7–10]. Increased
glutamate concentration has been reported in temporal and
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inferior parietal areas in AD, where an inability to remove
excess synaptic glutamate is considered to contribute to
cell death [11, 12].
Recent work by our group has demonstrated that the
human branched-chain aminotransferase (hBCAT)
enzymes, which regulate brain glutamate [reviewed in 13],
show increased expression in the brains of patients with AD
[14]. There are two isoforms, cytosolic (hBCATc,
43,400 Da) and mitochondrial (hBCATm, 41,730 Da) that
catalyse the reversible transamination of branched-chain
amino acids (BCAAs; leucine, isoleucine and valine) and a-
ketoglutarate to form their respective branched-chain a-ke-
toacids (BCKAs) and glutamate [15, 16]. The cytosolic
isoform shows tissue and cell specific expression, primarily
restricted to the brain and peripheral nervous system and is
found largely in neuronal cells, particularly in the axons and
nerve terminals of glutamatergic cells and in the cell bodies
of GABAergic neurons [17, 18]. This expression is consis-
tent with the hypothesis that hBCATc contributes to the
maintenance of metabolic glutamate pools [19]. In rat retina
models, gabapentin, an inhibitor of BCATc, impacted glu-
tamate synthesis by 30 % in isolated rat retina, also sup-
porting a role for BCAT metabolism in brain glutamate
metabolism [20, 21]. In AD brain, hBCATc showed regional
overexpression (:28 %), particular to the CA1 and CA4
regions, areas which show pathology at an early stage in AD
[14]. This increase could result in increased BCKAs and
glutamate indicating a role in neuronal toxicity or could also
be a response to toxic insult. Conversely, hBCATm, which is
specifically localised to endothelial cells of the vasculature,
is proposed to have a potential neuroprotective role by sup-
porting astrocytes through metabolism of excess glutamate
generated at the synapse [18]. However, the exact details of
this mechanism remain undetermined.
Compromised neurotransmitter profiles are also
notable in DLB and VaD. People with DLB exhibit
Parkinsonian symptoms which is caused by the accumu-
lation of widespread Lewy bodies (eosinophilic cytoplas-
mic inclusions with alpha-synuclein as their major
component), thus sharing common features with Parkin-
son’s disease (PD) pathology [22]. However, in PD, Lewy
bodies are primarily found in the substantia nigra and locus
coeruleus compared to the cortices and brainstem in DLB.
Moreover, DLB is often accompanied by varying degrees
of AD-related pathology (neuritic plaques and less fre-
quently neurofibrillary tangles), which is sometimes clas-
sified as pure DLB (no or minor AD-related changes) and
common DLB (marked AD-related pathology) [23].
Although the dopaminergic system is primarily compro-
mised in PD patients, dysregulated glutamatergic trans-
mission has also been reported [24–26]. In a sample set of
common DLB patients compared to pure AD cases, the
expression of metabotrophic glutamate receptors (mGluR)
were significantly decreased and correlated with increased
neurofibrillary tangle Braak stage, indicating a shared
pathogenesis across DLB and AD [27]. Moreover, experi-
mental models of Parkinsonism have indicated that mod-
ulation of mGluR was neuroprotective [28]. These studies
indicate that in both DLB and AD, glutamatergic trans-
mission is dysregulated and is likely to contribute to the
pathogenesis of these conditions.
The clinical characterisation of VaD is more complex. VaD
is a heterogeneous disorder largely resulting from neurode-
generation caused by cerebrovascular disease (e.g.
atherosclerosis, small vessel disease, lipohyalinosis and cere-
bral amyloid angiopathy) with different types of vascular
lesions [29, 30]. Cognitive decline can be difficult to distinguish
from AD but can result from any of a number of different
cerebrovascular events [31]. Yet, the neurochemical profile of
VaD shares commonalities with AD such as abnormalities in
the cholinergic system. Hypo-perfusion, another contributor to
VaD triggers hypoxia and glucose deprivation in nerve cells,
resulting in membrane depolarization followed by a release of
excess glutamate that causes glutamate toxicity [31]. Overall,
while different neurodegenerative mechanisms are involved in
AD, DLB and VaD, glutamate toxicity seems to be a common
feature that warrants further investigation particularly to gain
insights in its regulation.
In this study we first examined the distribution and
protein levels of hBCATc and hBCATm in the frontal and
temporal cortex in DLB and VaD cases compared to age-
and sex-matched controls. We then investigated expression
of hBCATc and hBCATm mRNA in this cohort and
additionally in a cohort of AD cases to explore whether
disease-specific differences in protein levels could be
attributable to altered mRNA expression. In this report we
highlight significant changes in the levels of hBCATm in
the frontal and temporal cortex of VaD cases and in the
frontal cortex of DLB cases compared to controls. Not only
was hBCATm protein increased multiple forms of the
enzyme were also observed—raising the possibility of a
neuroprotective role for BCATm or protein modification
response to the brain damage that occurs in these diseases.
These changes suggest a more global response, perhaps
reflecting general neurodegeneration, in response to
pathogenic challenges.
Materials and Methods
Details of Antibodies and Peptides
Rabbit polyclonal antibodies to hBCATc and hBCATm
were purchased from Insight Biotechnology (Wembley,
UK) and Abcam (Cambridge, UK). Mouse monoclonal
antibody to human glyceraldehyde 3-phosphate
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dehydrogenase (hGAPDH) was purchased from Santa Cruz
Biotechnology (California, USA). Western blot confirmed
the specificity of these antibodies; anti-hBCATc and anti-
hBCATm antibodies detected overexpressed hBCATc and
hBCATm proteins, respectively [18] and anti-hBCATc,
anti-hBCATm and anti-hGAPDH antibodies detected
hBCATc, hBCATm and hGAPDH in brain tissue homo-
genates at the expected molecular weights [18]. Previous
work has demonstrated the specificity of the hBCATc and
hBCATm antibodies for Western blot analysis and
immunohistochemistry [18].
Study Cohort
Brain tissue was obtained from the Human Tissue Author-
ity-licensed South West Dementia Brain Bank, University
of Bristol, and the study was conducted with approval by
North Somerset and South Bristol Research Ethics Com-
mittee. The brains had been divided mid-sagittal at autopsy:
the left cerebral hemisphere sliced and frozen at -80 C for
biochemical studies and the right cerebral hemisphere fixed
in 10 % buffered formalin for 3 weeks before embedding
required cut tissue blocks in paraffin for detailed neu-
ropathological assessment. The cohort studied included AD,
DLB, VaD and control brains. The AD group were selected
on the basis of diagnosis according to Consortium to
Establish a Registry for Alzheimer’s disease (CERAD)
criteria of ‘‘definite AD’’ [32] and had a Braak tangle stage
of IV–VI. DLB cases had all developed dementia before or
within 12 months of the onset of motor symptoms and had
multiple alpha-synuclein-positive Lewy bodies in the cere-
bral cortex and brain stem nuclei, usually including the
substantia nigra and the locus coeruleus. Most of these cases
also had mild to moderate Alzheimer’s disease-type patho-
logical changes, including Ab plaques, predominantly dif-
fuse, and neurofibrillary tangles amounting to Braak stages
0–IV. VaD cases had a clinical history of dementia, occa-
sional neuritic plaques (if present), a Braak tangle stage of
III or less, histopathological evidence of multiple infarcts/
ischemic lesions, moderate to severe atheroma and/or arte-
riosclerosis, and an absence of histopathological evidence of
other disease likely to cause dementia. Control cases had no
history of dementia, few or no neuritic plaques, a Braak
tangle stage of III or less, and no other neuropathological
abnormalities.
For biochemical analysis, we dissected samples of left
frontal and temporal cortex (Brodmann areas 9 and 22)
from 15 neuropathologically confirmed cases of AD (for
mRNA expression studies), 15 of DLB, 15 of VaD and 15
controls (for mRNA and protein studies), with groups
matched as closely as possible for age, sex, and post-
mortem delay (Table 1). Medical Research Council (MRC)
database identifiers, demographic and neuropathological
data for this cohort are also summarised in Table 1. For
immunoperoxidase staining, a subset of 5 brain tissue
samples from the DLB, VaD and control group were
selected, (paraffin sections from right frontal and temporal
lobe).
Immunoperoxidase Staining of hBCATc
and hBCATm in Paraffin Sections
Seven lm paraffin-embedded sections of brain tissue from
the frontal and temporal lobe were collected on 3-amino-
propyl-triethoxy-silane coated slides and placed at 40 C
overnight for drying. Before staining, slides were incubated
overnight at 60 C, dewaxed, hydrated, immersed in
methanol containing 3 % hydrogen peroxide to block
endogenous peroxidase activity, pre-treated by immersion
in boiling in citrate buffer (pH 6) and blocked by immer-
sion in 20 % normal horse serum (Vector Laboratories,
Peterborough, UK). Sections were then incubated over-
night primary antibody optimally diluted in phosphate
buffered saline (PBS) (Insight Biotechnology anti-hBCATc
1:1000, Abcam anti-hBCATc 1:100, Insight Biotechnology
and Abcam anti-hBCATm 1:1000, respectively). The fol-
lowing day, bound antibody was detected with biotinylated
universal secondary antibody and visualised with avidin–
biotin horseradish peroxidase complex (VectaElite ABC
complex kit, Vector Laboratories) and 3,30-diaminoben-
zidine containing \0.1 % H2O2 (DAB, Vector Laborato-
ries). Sections were subsequently immersed in 0.16 M
copper sulphate to enhance staining and counterstained by
immersion in Harris’ haematoxylin. Negative control sec-
tions (primary antibody omitted) were included with each
immunolabelling procedure. Images were acquired using a
Nikon eclipse 50i microscope.
Specificity of anti-hBCATc and anti-hBCATm anti-
bodies (Insight Biotechnology) for hBCATc and hBCATm,
respectively, was verified by adsorption experiments with
the immunising peptides. Antibodies were optimally dilu-
ted in PBS and incubated with a 200-fold molar excess of
immunising peptide overnight at 4 C with agitation.
Sections from a control case selected on the basis of having
strong hBCATc or hBCATm immunolabelling were incu-
bated in (1) unabsorbed anti-hBCATc/anti-hBCATm anti-
body (positive control) (2) preabsorbed antibody solution
and (3) PBS (negative control). The immunohistochemical
procedure was otherwise performed as above.
Preparation of Brain Tissue Homogenates
Frozen tissue (250 mg) from left midfrontal and temporal
lobe was homogenised in 1 mL of 1 % SDS lysis buffer
(0.1 mM NaCl, 10 mM Tris pH 6, 1 lM phenylmethyl-
sulfonyl fluoride, 1 lg/mL aprotinin, and 1 % SDS in
308 Neurochem Res (2017) 42:306–319
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Table 1 Brain tissue used in
the study
MRC database ID Case Age (years) Gender Post-mortem delay (h) Braak tangle stage
BBN_9039 DLB1 75 M 53 0
BBN_9064 DLB2 77 M 21 III
BBN_9135 DLB3 97 F 24 II
BBN_9297 DLB4 91 M 25 IV
BBN_9302 DLB5 83 M 28 IV
BBN_9305 DLB6 82 M 52 III–IV
BBN_9316 DLB7 76 F 33 III
BBN_9321 DLB8 86 M 15 III
BBN_9324 DLB9 95 M 21 III–IV
BBN_9334 DLB10 69 M 38 0
BBN_4198 DLB11 85 F 30 IV
BBN_9351 DLB12 79 F 26 II
BBN_4202 DLB13 75 M 69 IV
BBN_9370 DLB14 76 M 26 0
BBN_9384 DLB15 67 F 20 0
BBN_8662 VaD1 81 M 66 0
BBN_8667 VaD2 84 F 20 II
BBN_8669 VaD3 93 M 30 III
BBN_8675 VaD4 83 M 24 II
BBN_8724 VaD5 72 M 41 III
BBN_8799 VaD6 90 F 31 I
BBN_8861 VaD7 89 M 30 III
BBN_8927 VaD8 67 M 54 III
BBN_8944 VaD9 97 F 66 II
BBN_8952 VaD10 84 M 30 II
BBN_8975 VaD11 76 M 40 III
BBN_9108 VaD12 79 M 56 II
BBN_9224 VaD13 89 F 22 I
BBN_4208 VaD14 78 F 54 0
BBN_9387 VaD15 89 M 45 II
BBN_8853 AD1 96 F 53 IV
BBN_8960 AD2 78 M 22 V
BBN_8997 AD3 74 F 12 VI
BBN_9122 AD4 83 F 5 V
BBN_9182 AD5 74 M 24 V
BBN_9280 AD6 76 M 11 V
BBN_9295 AD7 85 M 50 VI
BBN_9304 AD8 61 M 38 V
BBN_9323 AD9 84 F 21 VI
BBN_9338 AD10 95 M 27 IV
BBN_9341 AD11 80 F 51 V
BBN_9343 AD12 80 M 24 IV
BBN_9346 AD13 88 F 64 VI
BBN_4200 AD14 69 M 72 VI
BBN_4204 AD15 65 M 39 V
BBN_8749 C1 88 F 28 II
BBN_8770 C2 89 F 15 II
BBN_8779 C3 69 M 66 II
BBN_8835 C4 73 F 59 I
BBN_8898 C5 83 F 24 II
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distilled water) in a Precellys 24 homogeniser (Stretton
Scientific, Derbyshire, UK). Total protein concentration for
each sample was measured using the Bradford Assay;
absorbance values were measured on a FluoStar OPTIMA
plate reader (BMG Labtech, Buckinghamshire, UK).
Measurement of hBCATc and hBCATm Protein
by Western Blot
Standard hBCAT proteins and brain tissue homogenates
were diluted in 19 NuPAGE LDS Sample Buffer (Life
Technologies, Paisley, UK) containing 5 % b-mercap-
toethanol (Sigma-Aldrich, Suffolk, UK) to final concen-
trations of 10 ng, 30 ng and 20 lg of protein, respectively.
Diluted samples were denatured by heating at 95 C for
5 min and electrophoresed alongside Spectra Multicolour
Broad Range Protein Ladder (Fisher Scientific UK Lim-
ited, Loughborough, UK) on a NuPAGE 4–12 % Bis–Tris
precast gel (Life Technologies) with NuPAGE MES SDS
Running Buffer (Life Technologies) for 1 h at 185 V.
Proteins were subsequently transferred to nitrocellulose
membrane (GE Healthcare, Chalfont St Giles, UK) in an X
Cell IITM Blot Module (Life Technologies) at 18 V over-
night at 10 C. Protein detection was performed using the
SNAP i.d. system (Millipore, Watford, UK) according to
the manufacturer’s instructions. Membranes were washed
in Tris-buffered saline Tween 20 [TBST (0.05 % Tween 20
in Tris-buffered saline—0.02 M Tris, 0.5 M NaCl, pH
7.5)], assembled in the SNAP i.d. manifold, blocked with
0.5 % non-fat dried milk powder in TBST (centrifuged at
2000g for 2 min, 30 mL applied with vacuum), probed
with primary antibody diluted in 0.5 % non-fat dried milk
powder in TBST (Insight Biotechnology anti-hBCATc
1:1000, Insight Biotechnology anti-hBCATm 1:1000,
Santa-Cruz anti-hGAPDH 1:4000) for 10 min, washed in
TBST (3 9 10 mL with vacuum), incubated with peroxi-
dase-conjugated secondary antibody (Vector Laboratories)
diluted in 0.5 % non-fat dried milk powder in TBST (anti-
rabbit 1:5000, anti-mouse 1:5000) for 10 min and washed
in TBST (3 9 10 mL with vacuum). All incubations were
conducted at room temperature. Membranes were subse-
quently removed from the SNAP i.d. manifold and
immunolabelled proteins visualised using Luminata Forte
Western HRP Substrate (Millipore) applied for 2 min,
followed by exposure to Amersham Hyperfilm ECL (GE
Healthcare, UK) for 1 min and developed. Each membrane
was probed twice; first for either hBCATc or hBCATm,
and after stripping of the membrane in 0.5 M NaOH
(5 min) and washing in TBST (3 9 10 min) for hGAPDH.
Films were scanned and band density was measured using
NIH Image J Software (developed by Wayne Rasband,
National Institute of Mental Health). For each case relative
hBCATc and hBCATm expression were adjusted for using
hGAPDH density.
RNA Extraction, Reverse Transcription and cDNA
Production
3–5 mm3 of frozen tissue from the left midfrontal region
and temporal lobe was homogenised in TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) in a Precellys 24
homogenizer, incubated for 3 min in chloroform and cen-
trifuged at 12,000g for 15 min at 4 C. The upper aqueous
phase was separated and mixed with an equal volume of
isopropanol and 30 lg of glycogen (Sigma-Aldrich),
incubated for 10 min, and centrifuged at 12,000g for
10 min at 4 C for ribonucleic acid (RNA) precipitation.
The RNA pellet was washed with 75 % ethanol, re-
Table 1 continued
MRC database ID Case Age (years) Gender Post-mortem delay (h) Braak tangle stage
BBN_8980 C6 72 F 24 0
BBN_8983 C7 78 M 48 I
BBN_9028 C8 76 M 23 II
BBN_9292 C9 73 M 35 III
BBN_9311 C10 93 M 38 III
BBN_9329 C11 80 M 46 0
BBN_9340 C12 94 F 21 II
BBN_9344 C13 92 M 35 II
BBN_9353 C14 94 M 40 II
BBN_9354 C15 85 M 31 II
MRC database identifiers, pathological and demographic data for individual cases
Key AD Alzheimer’s disease, C control, DLB dementia with Lewy bodies, F female, M male, VaD vascular
dementia
310 Neurochem Res (2017) 42:306–319
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suspended in water (Sigma-Aldrich), and treated with
DNase-I (40 U, Roche Diagnostics Ltd., West Sussex, UK)
to remove genomic DNA. RNA concentration was mea-
sured using the Ribogreen RNA Quantification Kit (Invit-
rogen) and a FluoStar OPTIMA plate reader (BMG
Labtech). RNA was reverse transcribed to complementary
DNA (cDNA) using the High Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA, USA): 100 ng of
RNA in a total volume of 100 lL was incubated at 25 C
for 10 min, 37 C for 2 h, followed by inactivation at
85 C for 5 s. cDNA concentration was determined using
the Picogreen DNA quantification kit (Invitrogen) and
FluoStar OPTIMA plate reader (BMG Labtech) according
to the manufacturer’s instructions.
Measurement of hBCATc and hBCATm mRNA
by Real-Time Polymerase Chain Reaction
Real-time polymerase chain reaction (PCR) was performed
using the Applied Biosystems StepOnePlusTM Real-Time
PCR system (Life Technologies) with Assay-on-Demand
Gene Expression Products (TaqMan Gene Expression
Assay probes, FAM dye-labelled, Life Technologies) for
BCAT1 (BCATc), BCAT2 (BCATm) and the calibrator
gene GAPDH (GAPDH). The 20 lL reaction mixture
comprised TaqMan Fast Universal PCR Master Mix
(TaqMan, Life Technologies), AOD gene expression
assay probe and 10 ng of cDNA. Experiment parameters
were set as 95 C for 20 s followed by 40 cycles of 95 C
for 1 s and 60 C for 20 s. Each sample was analysed in
triplicate and SD[ 0.2 were repeated. Relative hBCATc
and hBCATm mRNA expression was expressed as the fold
difference in hBCATc and hBCATm mRNA of each sub-
ject relative to the mean value in control tissue, calibrated
in relation to GAPDH (constitutively expressed by all cell
types)using the 2-DDCT method [33]. The mRNA levels
were therefore expressed as exponential functions, 2-DDCT
values were used to perform statistical tests and the results
were presented as the geometric mean with 95 % confi-
dence intervals for each group.
Statistical Analysis
Kruskall-Wallis test was used with Dunn’s test for pairwise
diagnosis group comparisons of hBCATc and hBCATm
mRNA expression. hBCATc and hBCATm protein levels
were compared between diagnosis groups by Mann–
Whitney U test and independent t test, respectively.
Spearman’s test was used to assess correlations of hBCATc
and hBCATm mRNA and protein levels with age and post-
mortem delay and Mann–Whitney U test was used to
assess hBCATc and hBCATm mRNA and protein levels in
relation to gender, for each diagnosis group and in groups
combined. p values \0.05 were considered statistically
significant
Results
Immunohistochemical Distribution of hBCATc
and hBCATm in Frontal and Temporal Neocortex
of VaD, DLB and Control Subjects
Immunolabelling with two anti-hBCATc antibodies con-
firmed that hBCATc is distributed in neurons in frontal and
temporal cortex (Fig. 1a–g). In all cases there was strong
immunolabelling of pyramidal cells in the CA3 and CA4
regions of the hippocampus, whereas neuronal immunola-
belling in CA2, CA1 and subiculum was relatively sparse.
The specificity of neuronal labelling was demonstrated,
where no immunopositive cells were observed following
pre-adsorption of the anti-hBCATc antibody (Insight
Biotechnology) with 200-fold molar excess of immunising
peptide. Immunolabelling with two anti-hBCATm anti-
bodies revealed labelling of the endothelial cell layer of
medium sized and large blood vessels, predominantly in
white matter, and to a lesser extent in the frontal and
temporal cortex (Fig. 2a–h). No other cell types were
immunopositive for hBCATm and the specificity of
hBCATm immunolabelling was determined by pre-ad-
sorption of the anti-hBCATm antibody (Insight Biotech-
nology) with 200-fold molar excess of immunising peptide.
These findings demonstrate that the cell-specific expression
of the hBCAT proteins is similar in all diseased conditions.
Levels of hBCATc and hBCATm Protein in Frontal
and Temporal Neocortex of VaD and DLB Brains
Relative to Age- and Gender-Matched Controls
hBCATc and hBCATm protein was measured by Western
blot analysis in frontal and temporal cortex of DLB, VaD
and control cases. The densitometry from each hBCAT
isoform was measured relative to the corresponding
GAPDH density in that homogenate (Figs. 3, 4) [14]. After
adjustment, the levels of hBCATc protein in frontal and
temporal cortex were similar in VaD and control groups
and were lower in DLB cases, but this did not reach sig-
nificance (Fig. 3b).
In contrast, adjusted hBCATm protein differed signifi-
cantly between VaD, DLB and control brains (Fig. 4b).
Adjusted hBCATm protein was significantly increased by
63 % in frontal and 20 % in temporal cortex of DLB cases
compared with the control group (frontal: p = 0.004,
temporal: p = 0.024) and were increased by 70 % in
frontal and 35 % in temporal cortex of VaD cases com-
pared to controls (frontal: p = 0.002, temporal p = 0.191).
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Fig. 1 Positive immunostaining for hBCATc in neuronal cells of
vascular dementia and dementia with Lewy bodies. Immunolabelling
with anti-hBCATc (Insight Biotechnology limited) showed that
hBCATc is localised to cortical neurons in frontal and temporal
cortex of control (a, b), vascular dementia (VaD) (c, d) and dementia
with Lewy bodies (DLB) cases (e, f). Immunolabelling with anti-
hBCATc (Abcam) confirmed this neuronal distribution in frontal
cortex of the control case (g). The specificity of labelling human brain
tissue was demonstrated by the lack of signal after pre-incubation of
anti-hBCATc (Insight Biotechnologies limited) with 200-fold molar
excess of immunising peptide (i, control case). The scale bar
represents 100 lm in a–h. DG dentate gyrus
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hBCATc and hBCATm mRNA Level in Frontal
and Temporal Neocortex
BCAT1 (hBCATc) and BCAT2 (hBCATm) expression
were measured by real-time PCR, along with the calibrator
gene GAPDH (hGAPDH: constitutively expressed in all
cell types and has similar expression between diagnosis
groups (see Supplementary Figure 1), therefore widely
used as a reference gene). In relation to hGAPDH mRNA,
hBCATc mRNA levels were similar in AD and control
cases in both frontal and temporal regions and were
increased in frontal and temporal cortex of DLB and VaD
cases compared to controls; however this increase was only
significant between the VaD group and the control group
(p\ 0.05) in the frontal cortex (Fig. 5).
Frontal and temporal hBCATm mRNA levels calibrated
in relation to hGAPDH mRNA did not significantly differ
between the diagnosis groups, although there was a twofold
increase of hBCATm mRNA in the frontal cortex of VaD
cases compared to controls and a decrease in hBCATm
mRNA in the temporal cortex of AD cases compared to
controls, but these did not reach significance (Fig. 6).
hBCATc and hBCATm in Relation to Gender, Age,
Post-mortem Delay and Braak Stage
Protein and mRNA measurements of hBCATc and
hBCATm did not vary significantly with gender and
showed no correlation with post-mortem delay, as previ-
ously reported [28] either in the individual diagnosis
groups or with the groups combined. There was a signifi-
cant positive correlation between hBCATm protein levels
and age in the temporal, but not frontal, cortex when
diagnosis groups were combined for analysis and in the
control group (Table 2) but no correlation with age for any
other datasets (hBCATc and hBCATm mRNA or hBCATc
protein). What is particularly striking, however, is the
presence of multiple bands between 41 and 52 kDa sug-
gesting post-translational modification of the BCATm
protein in the vasculature. A significant positive correlation
was observed between hBCATm protein expression and
Braak stage in both the temporal and frontal cortex
(Table 3).
Several steps were taken to ensure the accuracy of data
interpretations including assessment of the effects of
A B C
D
IHG
FE
Control
Control
VaD
VaD
DLB
DLB
Frontal
Temporal
Fig. 2 Positive immunostaining for hBCATm in endothelial cells of
vascular dementia and dementia with Lewy bodies. Immunolabelling
in frontal (a–c) and temporal cortex (d–f) with anti-hBCATm (Insight
Biotechnology limited) showed that hBCATm is present in the walls
of some cortical arterioles in control (a, d), vascular dementia (VaD)
(b, e) and dementia with Lewy bodies (DLB) cases (c, f).
Immunolabelling with anti-hBCATm (Abcam) confirmed this vascu-
lar distribution in frontal (g) and temporal cortex (h) of a control case.
The specificity of labelling of human brain tissue was demonstrated
by the lack of signal after preincubation of anti-hBCATm (Insight
Biotechnologies limited) with 200-fold molar excess of immunising
peptide (i, control case). The scale bar represents 100 lm
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demographic variables (age, gender and post-mortem
delay) on all data sets. Of particular interest from these
analyses was the observed positive correlation between age
and temporal hBCATm protein expression that was sig-
nificant when the diagnosis groups were combined for
analysis and in the control group. Absence of this corre-
lation in the DLB and VaD groups suggests that the effect
of age on hBCATm protein expression is masked by the
disease process in which hBCATm expression is elevated.
Discussion
The incidence of late-onset dementia is predicted to
increase three-fold within the next 40 years [1]. This calls
for an urgent need for better understanding of the aetiolo-
gies of dementias to identify specific drug targets and
design effective disease modifying therapeutics. Under-
standing the profiles and roles of the hBCAT isoenzymes in
the CNS may facilitate this, as well as the design of ther-
apeutic compounds that may treat disturbances of the
glutamatergic system. In this study we report that the
distribution and expression of hBCATc, the neuronal
specific protein, is unchanged in DLB and VaD in the
frontal and temporal cortex suggesting that in these areas
neuronal glutamate metabolism is not affected by BCAA
metabolic enzymes. However, Western blot analysis
demonstrated a significant increase in the hBCATm protein
in the brains of VaD and DLB. Which was also reported in
AD brain [14]. Under all disease conditions multiple forms
of hBCATm were reported. There was also a twofold
increase in hBCATm mRNA in the frontal region of
patients with VaD relative to controls, however, this was
not observed for the DLB cohort or in the temporal region
of VaD, indicating possible alternative mechanisms of
hBCATm regulation between conditions and or funda-
mental differences in the molecular aspects of the disease.
Under normal excitatory conditions a cyclical process
exists whereby excess glutamate within the synaptic cleft is
taken up by astrocytes and converted to glutamine that is
then released to the extracellular fluid for subsequent
uptake by pre-synaptic neuronal cells, thereby replenishing
neuronal glutamate [34]. However, not all neuronal gluta-
mate is replenished as it is ‘‘lost’’ through oxidation for
Fig. 3 hBCATc protein in frontal and temporal cortex. a (frontal and
temporal) Representative Western blot probed with anti-hBCATc,
followed by anti-GAPDH. For all Western blots, Lane 1 molecular
weight markers, Lane 2 overexpressed purified hBCATc, Lanes 3–4
control, Lanes 5–7 dementia with Lewy bodies (DLB) and Lanes 8–9
vascular dementia (VaD) homogenates. Anti-hBCATc antibody
detected a single band of 43 kDa from overexpressed hBCATc
protein and in brain homogenates. b Graphs showing hBCATc protein
level in frontal and temporal cortex in control, DLB and VaD. The
horizontal bars indicate the mean and 95 % confidence intervals for
each group and each point represents an individual brain
314 Neurochem Res (2017) 42:306–319
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energy or used as a source of carbon for the production of
purines and reducing equivalents such as glutathione [35],
but only when glutamate concentrations are high [36, 37].
Here, the BCAAs serve as nitrogen donors to replace this
‘‘lost’’ glutamate and contribute up to 30 % of nitrogen for
de novo glutamate synthesis [20, 21, 38–40]. This cycling
Fig. 4 hBCATm protein in frontal and temporal cortex. a represen-
tative Western blot probed with anti-hBCATm, followed by GAPDH.
Densitometry measured the bands specific for hBCATm, as indicated
on the blot. For all Western blots, Lane 1 molecular weight markers
and Lane 2 overexpressed hBCATm, Frontal: Lanes 3–4 VaD, Lanes
5–6 DLB and Lanes 7–9 control homogenates; Lane 10 AD,
Temporal: Lanes 3, 5, 11 control, Lanes 4, 6, 7 DLB and Lanes
8–10 VaD. Anti-hBCATm antibody detected a single band of 41 kDa
from overexpressed hBCATm protein and in frontal and temporal
homogenates bands between 41 and 52 kDa. b Graphs showing
hBCATm protein level in frontal and temporal cortex in control, DLB
and VaD. The horizontal bars indicate the mean and 95 % confidence
intervals for each group and each point represents an individual brain
Fig. 5 hBCATc mRNA in the frontal and temporal cortex. hBCATc
mRNA was measured by real-time PCR in the frontal (a) and
temporal cortex (b) of control, Alzheimer’s disease (AD), dementia
with Lewy bodies (DLB) and vascular dementia (VaD) cases. Fold
change in BCAT1 expression in relation to GAPDH was calculated
using the 2-DDCt method. Graphs show individual data points along
with geometric mean and 95 % confidence intervals for each group on
a logarithmic scale to the base 2
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and regulation maintains levels of neuronal glutamate and
prevents toxicity in the synaptic space. However, under
conditions where toxicity prevails (such as AD), we have
previously demonstrated that hBCATc showed a regional
increase in expression in the hippocampus, which could
contribute to excess glutamate, described for AD [14].
Increased hBCATm in the endothelial cells of the vascu-
lature was also reported, where a role for hBCATm in
neuroprotection was proposed. Here, in this study, we show
that the levels of hBCATm are also significantly increased
in VaD and DLB, suggesting that the response of this
mitochondrial enzyme is a more global reaction, perhaps
reflecting a response of the vasculature to general neu-
rodegeneration, in response to pathogenic challenges. We
hypothesize that in this instance, if glutamate levels are
very high, hBCATm could metabolise glutamate, reflecting
the importance of endothelial cells under excitotoxic con-
ditions. Endothelial cells express the excitatory amino acid
transporters (EAAT), and can accommodate high concen-
trations of glutamate, where a concentration gradient in
favour of glutamate efflux to blood has been proposed [41].
However, expression of hBCATm in endothelial cells
Fig. 6 hBCATm mRNA in the frontal and temporal cortex.
hBCATm mRNA was measured by real-time PCR in the frontal
(a) and temporal cortex (b) of control, Alzheimer’s disease (AD),
dementia with Lewy bodies (DLB) and vascular dementia (VaD)
cases. Fold change in BCAT2 expression in relation to GAPDH was
calculated using the 2-DDCt method. Graphs show individual data
points along with the geometric mean and 95 % confidence intervals
for each group on a logarithmic scale to the base 2. hBCATm mRNA
expression levels were not significantly different between the groups
in either of the brain regions
Table 2 Statistical analysis of the correlation between hBCATm protein in frontal and temporal cortex with age
Brain region Analysis of correlation between hBCATm protein level and age by Spearman’s correlation
p value, r value
DLB group (n = 15) VaD group (n = 15) Control group (n = 15) Groups combined (n = 45)
Frontal cortex 0.927, -0.026 0.465, ?0.204 0.104, ?0.453 0.177, ?0.207
Temporal cortex 0.237, ?0.325 0.980, ?0.007 0.001*, ?0.793 0.024*, ?0.340
Data are p values and r values (Spearman’s correlation) of correlation between hBCATm levels and age in frontal and temporal cortex
Key DLB dementia with Lewy bodies, VaD vascular dementia
* Indicates that correlation is significant at the 0.05 level
Table 3 Statistical analysis of the correlation between hBCATm protein in frontal and temporal cortex with Braak stage
Brain region Analysis of correlation between hBCATm protein level and Braak stage by Spearman’s correlation
p value, r value
DLB group (n = 15) VaD group (n = 15) Control group (n = 15) Groups combined (n = 45)
Frontal cortex 0.235, ?0.202 0.492, ?0.006 0.409, -0.065 0.047*, ?0.259
Temporal cortex 0.016*, ?0.555 0.471, ?0.021 0.477, -0.016 0.020*, ?0.312
Data are p values and r values (Spearman’s correlation) of correlation between hBCATm levels and Braak stage in frontal and temporal cortex
Key DLB dementia with Lewy bodies, VaD vascular dementia
* Indicates that correlation is significant at the 0.05 level
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indicates that glutamate can also be metabolised [18]. We
have also observed that Glutamate dehydrogenase (GDH)
is expressed in these cells (unpublished data), it too can
metabolise glutamate generating ammonia and a-keto
glutarate. Of course astrocytes are thought to be the main
site for glutamate metabolism and uptake, but in conditions
such as AD, VaD and DLB, where their role in glutamate
clearance is compromised, a support role for the BBB may
be important or they may enhance toxicity [42]. Recent
studies have indicated that the group I metabotropic
receptors (mGluR1 and mGluR5) are altered in post-mor-
tem brains of patients with DLB and may contribute to the
AD-like cognitive impairment and plaques found in the
DLB brain [27]. The decrease in mGluR1 reported in
‘common’ DLB cases, was suggested to occur potentially
due to overstimulation by excess endogenous glutamate,
characteristically associated with human and animal mod-
els of AD models rather than DLB. As described above for
VaD, a reduced uptake of synaptic glutamate could signal
increased metabolism by endothelial cells, offering a neu-
roprotective role through hBCAT metabolism.
Endothelial cells have a high concentration of mito-
chondria where hBCATm resides [43]. Here, because the
concentration of L-glutamate is high, deamination in the
direction of a-keto glutarate synthesis is likely, which can
feed into the TCA cycle but more importantly reduce
toxicity to neuronal cells by removing glutamate. Although
evidence in support of auxiliary pathways to remove excess
glutamate from brain exist [44–46], the integrity of the
BBB is compromised in AD and also in VaD, where
increased fragmented vessels, increased capillary basement
membrane thickening and reduced microvascular density
are all observed [47]. This resonates particularly with VaD
as cognitive decline is associated with widespread small
vascular lesions, either alone or often coexisting with AD
[31]. Part of the neuropathology associated with VaD is
significant loss of hippocampal neuronal cells due to
impaired microcirculation. Disruptions or damage caused
by vascular lesions in this area may cause decreased
cerebral blood flow and hypoperfusion contributing to the
ischaemia-related damage. Not enough is known about the
role of the BBB in some of the less common dementias but
altered cerebral blood flow appears to be regional. There-
fore the increased hBCATm observed here appears to be a
common observation across all of the dementia sub-types,
suggesting the potential importance of the vasculature and
the BBB in the development of pathology in a number of
dementias, especially since hBCATm could serve to lower
or exacerbate glutamate concentrations, depending on the
direction of transamination.
Not only is the integrity of the BBB negated, as indi-
cated from our studies, we show that multiple bands for
hBCATm, not seen for hBCATc, feature in pathological
conditions. These higher molecular weight bands may
represent different variants of hBCATm or forms of the
protein with post-translational modifications, as there was
no significant change in mRNA expression. Mitochondria
are not only targets but also contribute to cellular stress and
in conditions where cellular stress is increased target
molecules including lipids, DNA and redox- sensitive
proteins are damaged. In response to starvation and
increased cellular stress, damaged mitochondria are tar-
geted for degradation, termed mitophagy [48]. Although
the underlying mechanisms are not clear current under-
standing suggests that mitophagy is defective in neurode-
generative conditions, contributing to the accumulation of
defective mitochondria [49]. This may in part explain why
hBCATm is increased. Moreover, our group previously
identified that hBCAT isoenzymes have a well-charac-
terised redox-sensitive CXXC motif located approximately
10 A˚ from the active site [50] and that hBCAT activity is
regulated by the redox potential of the cell in mechanisms
involving H2O2 and NO as oxidising agents [51, 52].
Protein S-glutathionylation is a reversible post-translational
modification that can modulate protein activity and has
been reported for hBCAT in AD [14]. The process of
S-glutathionylation increases globally during overt oxida-
tive stress and locally in the presence of reactive oxygen
species [53] and so is likely to be relevant in a number of
dementias. Thus, it is possible that post-translational
modification of hBCATm could also be causative of the
increased levels of hBCATm protein in dementia. This
would result in the reversible inactivation of this protein,
which may compromise its proposed role in neuroprotec-
tion. However, this will depend on the overall exposure to
cellular stress, as hBCATm is less easily oxidized. One
must also consider that if the function of hBCATm is
compromised, GDH metabolism of glutamate could
increase levels of ammonia further contributing to toxicity.
Thus, increased hBCATm expression may correlate with
the underlying vascular pathology of these neurodegener-
ative conditions and represent a new target to consider
when treating human brain excitotoxicity. This concept has
been tested in other fields where toxicity-associated dam-
age has been reported. As reviewed by Cederberg et al.,
[54] ischaemia, subarachnoid haemorrhage, and traumatic
brain injury have studied to determine the impact of
reducing blood glutamate to alleviate brain toxicity. All
studies suggested that by regulating these levels, i.e.,
lowering glutamate had a positive impact on pathology was
reported such as improved recovery, better neuron survival
and smaller stroke volume. Moreover, the activity of glu-
tamine synthetase that converts glutamate to glutamine, in
the cerebrospinal fluid was also found to be increased not
only in AD patients but also VaD and ALS, further indi-
cating that the glutamate/glutamine cycle is compromised
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in neurodegenerative conditions and that alteration of
blood glutamate may be beneficial in treating these toxic
episodes [55, 56].
There was no significant increase in hBCATc expres-
sion in either the frontal or temporal cortex of DLB,
indicating that hBCATc expression is not impacted in
these areas. However, our study does not exclude the
possibility that regional increases could occur in other
brain areas more prone to DLB pathology as has been
observed for the hippocampal region in AD. Interestingly,
hBCATc mRNA levels were increased in DLB and VaD
cases compared to controls and to AD cases, however
there were no corresponding increases in hBCATc pro-
tein. This could point to some secondary non-specific
expression that is less likely to be biologically meaningful
in neurons; however it may also point to disease-associ-
ated changes in translation or perhaps even changes at a
microRNA level.
Collectively, these studies indicate that astrocyte and
endothelial glutamate homoeostasis is dysregulated in neu-
rodegenerative conditions where glutamate toxicity features.
These studies support a role for hBCATm in protecting via
amination of aKG or alternatively enhancing toxicity via
leucine transaminaton in endothelial cells. However, the
compromised BBB and multi-variant forms of hBCATm
observed in these pathogenic conditions may explain why
these systems do not operate optimally in neurodegenerative
conditions. Future studies clarifying the importance of blood
glutamate scavengers may be an important therapeutic target
for these hard-to-treat conditions.
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